# REGENERON PHARMACEUTICALS, INC. (REGN) FY2025 Q1 P&L / Income Statement

- Company: REGENERON PHARMACEUTICALS, INC. (REGN)
- Period: 2025-01-01 to 2025-03-31
- Filing: Q1 FY2025 10-Q, filed 2025-04-29, accession number 0001804220-25-000022
- Page: https://plicit.ai/financials/regn/fy2025-q1-income-statement
- Chart image: https://plicit.ai/charts/regn-fy2025-q1-income-statement-sankey.png

## Chart details: Revenue by Product and Service by Geography

Income statement for 2025-01-01 through 2025-03-31. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenues**: 3,028,700,000 US dollars
- **Cost of revenue (calculated)**: 464,300,000 US dollars
- **Gross profit (calculated)**: 2,564,400,000 US dollars
- **Operating expenses (calculated)**: 1,972,700,000 US dollars
- **Income from operations**: 591,700,000 US dollars
- **Total other income (expense)**: 313,300,000 US dollars
- **Income before income taxes**: 905,000,000 US dollars
- **Income tax expense (benefit)**: 96,300,000 US dollars
- **Net income**: 808,700,000 US dollars
- **ELYEA HD And EYLEA - UNITED STATES**: 1,042,800,000 US dollars
- **ELYEA HD - UNITED STATES**: 306,800,000 US dollars
- **Evkeeza - UNITED STATES**: 30,900,000 US dollars
- **EYLEA Net Product Sales - UNITED STATES**: 736,000,000 US dollars
- **Inmazeb - Rest Of World**: 0 US dollars
- **Libtayo - UNITED STATES**: 192,500,000 US dollars
- **Libtayo - Rest Of World**: 92,600,000 US dollars
- **Praluent - UNITED STATES**: 56,800,000 US dollars
- **Undisclosed (calculated)**: 570,300,000 US dollars
- **Cost of goods sold, collaboration and contract manufacturing**: 464,300,000 US dollars
- **Other operating expense (income), net**: 0 US dollars
- **Research and development**: 1,327,400,000 US dollars
- **Acquired in-process research and development**: 12,300,000 US dollars
- **Selling, general, and administrative**: 633,000,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Chart details: Revenue by Product and Service

- Page: https://plicit.ai/financials/regn/fy2025-q1-income-statement/revenue-by-product-and-service
- Chart image: https://plicit.ai/charts/regn-fy2025-q1-revenue-by-product-and-service-sankey.png

Income statement for 2025-01-01 through 2025-03-31. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenues**: 3,028,700,000 US dollars
- **Cost of revenue (calculated)**: 464,300,000 US dollars
- **Gross profit (calculated)**: 2,564,400,000 US dollars
- **Operating expenses (calculated)**: 1,972,700,000 US dollars
- **Income from operations**: 591,700,000 US dollars
- **Total other income (expense)**: 313,300,000 US dollars
- **Income before income taxes**: 905,000,000 US dollars
- **Income tax expense (benefit)**: 96,300,000 US dollars
- **Net income**: 808,700,000 US dollars
- **Net product sales**: 1,415,600,000 US dollars
- **Collaboration revenue**: 1,531,200,000 US dollars
- **Other revenue**: 81,900,000 US dollars
- **Cost of goods sold, collaboration and contract manufacturing**: 464,300,000 US dollars
- **Other operating expense (income), net**: 0 US dollars
- **Research and development**: 1,327,400,000 US dollars
- **Acquired in-process research and development**: 12,300,000 US dollars
- **Selling, general, and administrative**: 633,000,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.